Our pharmaceutical CDMO delivers end-to-end oral solid dosage (OSD) and Dry Powder Inhalation (DPI) drug product services, from pre-formulation to cGMP released drug product. DEA Schedule I to V licensed. FDA inspected. Nine approved and six active commercial products manufactured for US and international markets.
Products approved from this site
Currently in active commercial manufacturing, US and international markets
Successful FDA inspections in the past 8 years
Successful regulatory audits in the past 8 years
Schedule I to V analytical and manufacturing licensed
Deliver cGMP drug product to the clinic faster.
Designed for early-phase programs that need speed without compromising quality or regulatory compliance.
Nine products have been approved for commercial for commercial manufacturing at this site. Eight of these products were developed at Tampa, FL and only one was transferred. Six products with active commercial manufacturing for US and international markets.
Highly skilled and dedicated team. Proven expertise from pre-clinical to commercial for oral solid and inhaled drug products. Our development experts work hand in hand with our manufacturing team to ensure consistent, reliable commercial supply.
Challenge |
How we solve it |
| Need to get to clinic fast | First-in-human quick-to-clinic option: cGMP drug product from drug substance with minimal formulation development. |
| Too many vendors across the lifecycle | One site: development, clinical manufacturing, QC, packaging, storage, regulatory. |
| DEA-scheduled compound complexity | DEA Schedule I to V analytical and manufacturing licenses in place. |
| Highly potent compound handling | Dedicated HPAPI containment for oral solid dosage and DPI manufacturing. |
| Regulatory submission risk | 5 FDA inspections. 12 non-US market audits. |
| Current CDMO has no proven path to commercial | 9 approvals. 6 products on market today. From this site. |
Full-lifecycle oral solid dosage and DPI drug product services, with format-specific development and manufacturing capabilities under a shared quality and regulatory framework.
PRE-FORMULATION
FORMULATION DEVELOPMENT
ANALYTICAL DEVELOPMENT
DOSAGE FORMS
PRECISION DOSING
SPECIAL CAPABILITIES
PRE-FORMULATION
FORMULATION DEVELOPMENT
ANALYTICAL DEVELOPMENT
DPI MANUFACTURING
PRECISION DOSING
SPECIAL CAPABILITIES
The following capabilities serve both product formats under the same quality system, team, and DEA licensing framework.
PRIMARY PACKAGING
SECONDARY PACKAGING
ANALYTICAL QC
STABILITY
MICROBIOLOGY
RAW MATERIALS
PRODUCT STORAGE
DOCUMENTATION
SUBMISSIONS
STRATEGY
Ask us about our first-in-human quick-to-clinic option for early-phase oral solid dosage and DPI programs. Contact us here.
Engage our CDMO solutions team at any stage in the lifecycle of a product, with full continuity of quality assurance, project management, and regulatory compliance throughout.
Our CDMO solutions support oral solid dosage and DPI programs across:
5 successful FDA inspections and 12 regulatory audits in the past 8 years, across five major health authorities. Quality assurance systems built for global regulatory compliance from day one.
United States
United Kingdom
Brazil
Turkey
Russia
Need early-stage formulation development? Explore Innovaform® Accelerator, our European center for custom capsule design and DPI formulation development, with a structured pathway for cGMP transfer to our Tampa CDMO site.
Talk to our CDMO solutions team about first-in-human clinical supply, cGMP manufacturing, packaging, or commercial scale-up. Contact us here.
Capsules & Health Ingredients